Semin Thromb Hemost 2011; 37(6): 673-681
DOI: 10.1055/s-0031-1291377
© Thieme Medical Publishers

Congenital Amegakaryocytic Thrombocytopenia: Clinical Presentation, Diagnosis, and Treatment

Matthias Ballmaier1 , Manuela Germeshausen1
  • 1Department of Pediatric Hematology and Oncology/Molecular Hematopoiesis, Hannover Medical School, Hannover, Germany
Further Information

Publication History

Publication Date:
18 November 2011 (online)

ABSTRACT

Congenital amegakaryocytic thrombocytopenia (CAMT, MIM #604498) is a rare inherited bone marrow failure syndrome presenting as isolated hypomegakaryocytic thrombocytopenia at birth without other characteristic physical anomalies. Most of the patients develop a severe aplastic anemia and trilineage cytopenia during the first years of life and hematopoietic stem cell transplantation is the only curative treatment. In most of the cases the disease is caused by homozygous or compound heterozygous mutations in the gene MPL encoding the receptor for the hematopoietic growth factor thrombopoietin. The present review summarizes clinical and laboratory data for 96 patients with CAMT, reported since 1990.

REFERENCES

  • 1 Online Mendelian Inheritance in Man . Amegakaryocytic thrombocytopenia, congenital; CAMT.  http://www.ncbi.nlm.nih.gov/omim/604498 (Feb 25, 2011)
  • 2 Ihara K, Ishii E, Eguchi M et al.. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia.  Proc Natl Acad Sci U S A. 1999;  96 (6) 3132-3136
  • 3 Ballmaier M, Germeshausen M, Schulze H et al.. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia.  Blood. 2001;  97 (1) 139-146
  • 4 Kaushansky K. Thrombopoietin: the primary regulator of platelet production.  Blood. 1995;  86 (2) 419-431
  • 5 Ballmaier M, Germeshausen M. Advances in the understanding of congenital amegakaryocytic thrombocytopenia.  Br J Haematol. 2009;  146 (1) 3-16
  • 6 Auerbach A D. A test for Fanconi's anemia.  Blood. 1988;  72 (1) 366-367
  • 7 Freedman M H. Congenital Marrow Failure Syndromes and Malignant Hematopoietic Transformation.  Oncologist. 1996;  1 (6) 354-360
  • 8 Guinan E C, Lee Y S, Lopez K D et al.. Effects of interleukin-3 and granulocyte-macrophage colony-stimulating factor on thrombopoiesis in congenital amegakaryocytic thrombocytopenia.  Blood. 1993;  81 (7) 1691-1698
  • 9 Muraoka K, Ishii E, Tsuji K et al.. Defective response to thrombopoietin and impaired expression of c-mpl mRNA of bone marrow cells in congenital amegakaryocytic thrombocytopenia.  Br J Haematol. 1997;  96 (2) 287-292
  • 10 Henter J I, Winiarski J, Ljungman P, Ringdén O, Ost A. Bone marrow transplantation in two children with congenital amegakaryocytic thrombocytopenia.  Bone Marrow Transplant. 1995;  15 (5) 799-801
  • 11 Muraoka K, Ishii E, Ihara K et al.. Successful bone marrow transplantation in a patient with c-mpl-mutated congenital amegakaryocytic thrombocytopenia from a carrier donor.  Pediatr Transplant. 2005;  9 (1) 101-103
  • 12 MacMillan M L, Davies S M, Wagner J E, Ramsay N K. Engraftment of unrelated donor stem cells in children with familial amegakaryocytic thrombocytopenia.  Bone Marrow Transplant. 1998;  21 (7) 735-737
  • 13 Guinan E C, Boussiotis V A, Neuberg D et al.. Transplantation of anergic histoincompatible bone marrow allografts.  N Engl J Med. 1999;  340 (22) 1704-1714
  • 14 Lackner A, Basu O, Bierings M et al.. Haematopoietic stem cell transplantation for amegakaryocytic thrombocytopenia.  Br J Haematol. 2000;  109 (4) 773-775
  • 15 van den Oudenrijn S, Bruin M, Folman C C et al.. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia.  Br J Haematol. 2000;  110 (2) 441-448
  • 16 van den Oudenrijn S, de Haas M, von dem Borne A E. Screening for c-mpl mutations in patients with congenital amegakaryocytic thrombocytopenia identifies a polymorphism.  Blood. 2001;  97 (11) 3675-3676
  • 17 van den Oudenrijn S, Bruin M, Folman C C, Bussel J, de Haas M, von dem Borne A E. Three parameters, plasma thrombopoietin levels, plasma glycocalicin levels and megakaryocyte culture, distinguish between different causes of congenital thrombocytopenia.  Br J Haematol. 2002;  117 (2) 390-398
  • 18 King S, Germeshausen M, Strauss G, Welte K, Ballmaier M. Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients.  Br J Haematol. 2005;  131 (5) 636-644
  • 19 Germeshausen M, Ballmaier M, Welte K. MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease.  Hum Mutat. 2006;  27 (3) 296
  • 20 Yeşilipek H V, Hazar V, Küpesiz A, Yegin O. Peripheral stem cell transplantation in a child with amegakaryocytic thrombocytopenia.  Bone Marrow Transplant. 2000;  26 (5) 571-572
  • 21 Kudo K, Kato K, Matsuyama T, Kojima S. Successful engraftment of unrelated donor stem cells in two children with congenital amegakaryocytic thrombocytopenia.  J Pediatr Hematol Oncol. 2002;  24 (1) 79-80
  • 22 Al-Ahmari A, Ayas M, Al-Jefri A, Al-Mahr M, Rifai S, El-Solh H. Allogeneic stem cell transplantation for patients with congenital amegakaryocytic thrombocytopenia (CAT).  Bone Marrow Transplant. 2004;  33 (8) 829-831
  • 23 Steele M, Hitzler J, Doyle J J et al.. Reduced intensity hematopoietic stem-cell transplantation across human leukocyte antigen barriers in a patient with congenital amegakaryocytic thrombocytopenia and monosomy 7.  Pediatr Blood Cancer. 2005;  45 (2) 212-216
  • 24 Gandhi M J, Pendergrass T W, Cummings C C, Ihara K, Blau C A, Drachman J G. Congenital amegakaryocytic thrombocytopenia in three siblings: molecular analysis of atypical clinical presentation.  Exp Hematol. 2005;  33 (10) 1215-1221
  • 25 Passos-Coelho J L, Sebastião M, Gameiro P et al.. Congenital amegakaryocytic thrombocytopenia—report of a new c-mpl gene missense mutation.  Am J Hematol. 2007;  82 (3) 240-241
  • 26 Pemberton L C, Levett D, Skinner R, Hall A G, Hanley J P. Novel mutations in a child with congenital amegakaryocytic thrombocytopenia.  Br J Haematol. 2006;  135 (5) 742-743
  • 27 Savoia A, Dufour C, Locatelli F et al.. Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations.  Haematologica. 2007;  92 (9) 1186-1193
  • 28 Tonelli R, Scardovi A L, Pession A et al.. Compound heterozygosity for two different amino-acid substitution mutations in the thrombopoietin receptor (c-mpl gene) in congenital amegakaryocytic thrombocytopenia (CAMT).  Hum Genet. 2000;  107 (3) 225-233
  • 29 Maserati E, Panarello C, Morerio C et al.. Clonal chromosome anomalies and propensity to myeloid malignancies in congenital amegakaryocytic thrombocytopenia (OMIM 604498).  Haematologica. 2008;  93 (8) 1271-1273
  • 30 Desai S R, Ranade S R. Congenital amegakaryocytic thrombocytopenia (CAMT): a case report with review of literature.  Indian J Pathol Microbiol. 2007;  50 (3) 659-660
  • 31 Steinberg O, Gilad G, Dgany O et al.. Congenital amegakaryocytic thrombocytopenia-3 novel c-MPL mutations and their phenotypic correlations.  J Pediatr Hematol Oncol. 2007;  29 (12) 822-825
  • 32 Tamary H, Nishri D, Yacobovich J et al.. Frequency and natural history of inherited bone marrow failure syndromes: the Israeli Inherited Bone Marrow Failure Registry.  Haematologica. 2010;  95 (8) 1300-1307
  • 33 Bastida Eizaguirre M, Pereda Vicandi A, Pujana Zaldegui I. [Congenital amegakaryocytic thrombocytopenia in a 12 year old boy with no signs of pancytopenia: molecular analysis].  An Pediatr (Barc). 2008;  68 (4) 353-356
  • 34 Kanaji S, Kanaji T, Migita M et al.. Characterization of a patient with atypical amegakaryocytic thrombocytopenia.  Eur J Haematol. 2008;  80 (4) 361-364
  • 35 Fox N E, Chen R, Hitchcock I, Keates-Baleeiro J, Frangoul H, Geddis A E. Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature.  Exp Hematol. 2009;  37 (4) 495-503
  • 36 Rose M J, Nicol K K, Skeens M A, Gross T G, Kerlin B A. Congenital amegakaryocytic thrombocytopenia: the diagnostic importance of combining pathology with molecular genetics.  Pediatr Blood Cancer. 2008;  50 (6) 1263-1265
  • 37 Frangoul H, Keates-Baleeiro J, Calder C et al.. Unrelated bone marrow transplant for congenital amegakaryocytic thrombocytopenia: report of two cases and review of the literature.  Pediatr Transplant. 2010;  14 (4) E42-E45
  • 38 Chung H S, Koh K N, Kim H J et al.. A novel nonsense mutation in the MPL gene in congenital amegakaryocytic thrombocytopenia.  Pediatr Blood Cancer. 2011;  56 (2) 304-306
  • 39 Conde N, Quintero A E, Rives S et al.. Congenital amegakaryocytic thrombocytopenia (CAMT): a difficult early diagnosis.  Haematologica. 2010;  95 (Suppl 2) 412-413
  • 40 Martinón-Torres N, Vázquez-Donsión M, Loidi L, Couselo J M. CAMT in a female with developmental delay, facial malformations and central nervous system anomalies.  Pediatr Blood Cancer. 2011;  56 (3) 452-453
  • 41 Poles A, Keen L, Steward C et al.. Identification of mutations in the C-MPL gene confirms diagnosis of congenital amegakaryocytic thrombocytopenia (CAMT).  [abstract] Int J Immunogenet. 2010;  37 (5) 423
  • 42 Alter B P. Inherited bone marrow failure syndromes. In: Nathan D G, Stranahan R A, Orkin S H, Look A T, Ginsburg D, eds. Nathan and Oski's Hematology of Infancy and Childhood. 6th ed. Philadelphia: Saunders W.B.; 2003: 280-365
  • 43 Dame C, Wolber E M, Freitag P, Hofmann D, Bartmann P, Fandrey J. Thrombopoietin gene expression in the developing human central nervous system.  Brain Res Dev Brain Res. 2003;  143 (2) 217-223
  • 44 Ehrenreich H, Hasselblatt M, Knerlich F et al.. A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain.  Proc Natl Acad Sci U S A. 2005;  102 (3) 862-867
  • 45 Ivanova A, Wuerfel J, Zhang J, Hoffmann O, Ballmaier M, Dame C. Expression pattern of the thrombopoietin receptor (Mpl) in the murine central nervous system.  BMC Dev Biol. 2010;  10 77
  • 46 Hoffmann O, Rung O, Im A R et al.. Thrombopoietin contributes to neuronal damage in experimental bacterial meningitis.  Infect Immun. 2011;  79 (2) 928-936
  • 47 Khabbaze Y, Karayalcin G, Paley C, Shende A, Valderrama E, Lipton J M. Thrombocytopenia absent corpus callosum syndrome: third case of a distinct clinical entity.  J Pediatr Hematol Oncol. 2001;  23 (7) 469-471
  • 48 Knight S W, Heiss N S, Vulliamy T J et al.. Unexplained aplastic anaemia, immunodeficiency, and cerebellar hypoplasia (Hoyeraal-Hreidarsson syndrome) due to mutations in the dyskeratosis congenita gene, DKC1.  Br J Haematol. 1999;  107 (2) 335-339
  • 49 Geddis A E. Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii.  Hematol Oncol Clin North Am. 2009;  23 (2) 321-331
  • 50 Souyri M, Vigon I, Penciolelli J-F, Heard J M, Tambourin P, Wendling F. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors.  Cell. 1990;  63 (6) 1137-1147
  • 51 Beer P A, Ortmann C A, Stegelmann F et al.. Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms.  Haematologica. 2010;  95 (12) 2153-2156
  • 52 Bagby G C, Meyers G. Bone marrow failure as a risk factor for clonal evolution: prospects for leukemia prevention.  Hematology (Am Soc Hematol Educ Program). 2007;  40-46
  • 53 Roberts I, Stanworth S, Murray N A. Thrombocytopenia in the neonate.  Blood Rev. 2008;  22 (4) 173-186
  • 54 Giampietro P F, Verlander P C, Davis J G, Auerbach A D. Diagnosis of Fanconi anemia in patients without congenital malformations: an international Fanconi Anemia Registry Study.  Am J Med Genet. 1997;  68 (1) 58-61
  • 55 Basel-Vanagaite L, Dokal I, Tamary H et al.. Expanding the clinical phenotype of autosomal dominant dyskeratosis congenita caused by TERT mutations.  Haematologica. 2008;  93 (6) 943-944
  • 56 Mehta P, Locatelli F, Stary J, Smith F O. Bone marrow transplantation for inherited bone marrow failure syndromes.  Pediatr Clin North Am. 2010;  57 (1) 147-170
  • 57 Shimamura A, Alter B P. Pathophysiology and management of inherited bone marrow failure syndromes.  Blood Rev. 2010;  24 (3) 101-122
  • 58 Bizzetto R, Bonfim C, Rocha V Eurocord and SAA-WP from EBMT et al. Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia.  Haematologica. 2011;  96 (1) 134-141
  • 59 Cocault L, Bouscary D, Le Bousse Kerdiles C et al.. Ectopic expression of murine TPO receptor (c-mpl) in mice is pathogenic and induces erythroblastic proliferation.  Blood. 1996;  88 (5) 1656-1665
  • 60 Yan X Q, Lacey D L, Saris C et al.. Ectopic overexpression of c-mpl by retroviral-mediated gene transfer suppressed megakaryopoiesis but enhanced erythropoiesis in mice.  Exp Hematol. 1999;  27 (9) 1409-1417
  • 61 Wicke D C, Meyer J, Buesche G et al.. Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia.  Mol Ther. 2010;  18 (2) 343-352
  • 62 Lannutti B J, Epp A, Roy J, Chen J, Josephson N C. Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis.  Blood. 2009;  113 (8) 1778-1785
  • 63 Heckl D, Wicke D C, Brugman M H et al.. Lentiviral gene transfer regenerates hematopoietic stem cells in a mouse model for Mpl-deficient aplastic anemia.  Blood. 2011;  117 (14) 3737-3747

Matthias BallmaierPh.D. 

Pediatric Hematology and Oncology/Molecular Hematopoiesis, OE9411 - J11-H0-1110, Medizinische Hochschule Hannover

Carl-Neuberg- Strasse 1, D-30625 Hannover, Germany

Email: Ballmaier.Matthias@mh-hannover.de